Samjin Pharmaceutical Holds 54th Annual General Meeting of Shareholders... CEO Choi Yong-ju Reappointed

[Asia Economy Reporter Lee Gwan-joo] Samjin Pharmaceutical announced on the 28th that it held the 54th regular general meeting of shareholders on the 25th and reappointed CEO Choi Yong-ju as president.

Additionally, Samjin Pharmaceutical reported through its management performance report that it achieved sales of 250.1 billion KRW and an operating profit of 33.9 billion KRW last year. To enhance shareholder value, it also decided on a cash dividend of 800 KRW per share, the same as the previous year. The reappointment of outside director and audit committee member Han Sang-beom, as well as the new appointment of outside director and audit committee member Ko Ki-young, were approved as originally proposed.

This year’s key management strategies were also presented. It reported that it will focus on laying the foundation to leap forward as a total healthcare company by aiming for continuous performance creation through diversification of business areas such as prescription drugs, over-the-counter drugs, health functional foods, and medical devices.

Specifically, in the ‘Pharmaceuticals Division,’ core capabilities will be concentrated on expanding the market share of the anticoagulant ‘Rivoxaban’ and the growth of co-promotion items. The ‘Consumer Health Division’ plans to launch various products that can meet consumer needs along with the growth of the premium health supplement ‘Haru Engine.’

In the ‘Healthcare Division,’ stable market establishment of the wearable electrocardiogram measuring device ‘SPatch’ is expected, and in the ‘Research and Development Division,’ full efforts will be made to achieve results such as the development of global innovative new drugs and core technologies through the open innovation strategy of the Magok Research Center, which was completed last year.

CEO Jang Hong-soon said, “Although there will be various internal and external difficulties this year as well, we will spare no effort to become a total healthcare company,” adding, “Through this, all employees will do their best with a new determination to contribute to public health.”